Should Investors Worry About Moderna Slowing Enrollment in Its Coronavirus Vaccine Trial?
Earlier this year, Moderna (NASDAQ: MRNA) quickly emerged as a leader in the race to develop a coronavirus vaccine. The biotech's messenger RNA (mRNA) technology helped Moderna move faster than most companies in advancing a vaccine candidate into clinical tests in humans.
Today, Moderna stands as one of nine drugmakers with COVID-19 vaccine candidates in late-stage testing. The company is already more than six weeks into its phase 3 clinical trial of its vaccine candidate mRNA-1273. But Moderna revealed last week that it's slowing down enrollment in the study. Should investors be worried? No. Here's why.
Image source: Getty Images.
Source Fool.com
